Hope for regenerative treatments: toward safe transplantation of human pluripotent stem-cell-based therapies

Open Access Editorial by Robert Lanza and Erin A Kimbrel (Ocata Therapeutics, Santa Monica, CA, USA), on the immediate future of human pluripotent stem-cell-based therapies.

Go to the profile of Regenerative Medicine
Apr 07, 2015
0
0
Upvote 0 Comment

Induced pluripotent stem cells (iPSCs) could help treat a wide variety of diseases as a cell-based therapy, but tumorigenesis and immunogenicity are potential safety risks, and technical hurdles in directing their in vitro differentiation have thwarted efforts to bring iPSC-based therapies to the clinic. ESCs have similar safety issues, as well as the ethical concern over use of embryonic tissue. The below article discusses the status of PSC-based therapies in regenerative medicine, including safety considerations, currently approved clinical trials and a look at what is on the horizon.

Kimbrel EA, Lanza R. Hope for regenerative treatments: toward safe transplantation of human pluripotent stem-cell-based therapies. Regen. Med. (10)2, 99–102 (2015).

Author for correspondence: rlanza@ocata.com

Go to the profile of Regenerative Medicine

Regenerative Medicine

Journal, Future Science Group

Regenerative Medicine is an award-winning peer-reviewed journal, in print and web formats. The journal provides a forum to address the important challenges and advances in stem cell research and regenerative medicine, delivering this essential information in concise, clear and attractive article formats. Among other indexing services Regenerative Medicine is listed by MEDLINE/Index Medicus, EMBASE/Excerpta Medica, Chemical Abstracts, Science Citation Index Expanded™ (SciSearch®), Emcare, Biological Abstracts, BIOSIS Previews, Biotechnology Citation Index®, Journal Citation Reports/Science Edition®, Scopus® with an Impact Factor of 2.786 (2014). Each issue contains expertly drafted Reviews, Original Research articles, Perspectives, Editorials, topical insight from international leaders in their field, and additional added-value content. The Senior Editor of the journal is Professor Chris Mason, University College London. You can find out more about Regenerative Medicine at our website (www.future-science-group.com/journalprofile/regenerative-medicine/), where you can find the aims and scope of the journal and details of our international editorial board.

No comments yet.